149 related articles for article (PubMed ID: 38762686)
21. Novel peptide linkers for highly potent antibody-auristatin conjugate.
Doronina SO; Bovee TD; Meyer DW; Miyamoto JB; Anderson ME; Morris-Tilden CA; Senter PD
Bioconjug Chem; 2008 Oct; 19(10):1960-3. PubMed ID: 18803412
[TBL] [Abstract][Full Text] [Related]
22. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates.
Sutherland MS; Sanderson RJ; Gordon KA; Andreyka J; Cerveny CG; Yu C; Lewis TS; Meyer DL; Zabinski RF; Doronina SO; Senter PD; Law CL; Wahl AF
J Biol Chem; 2006 Apr; 281(15):10540-7. PubMed ID: 16484228
[TBL] [Abstract][Full Text] [Related]
23. Microtubule and tubulin binding and regulation of microtubule dynamics by the antibody drug conjugate (ADC) payload, monomethyl auristatin E (MMAE): Mechanistic insights into MMAE ADC peripheral neuropathy.
Best RL; LaPointe NE; Azarenko O; Miller H; Genualdi C; Chih S; Shen BQ; Jordan MA; Wilson L; Feinstein SC; Stagg NJ
Toxicol Appl Pharmacol; 2021 Jun; 421():115534. PubMed ID: 33852878
[TBL] [Abstract][Full Text] [Related]
24. Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates.
Law CL; Gordon KA; Toki BE; Yamane AK; Hering MA; Cerveny CG; Petroziello JM; Ryan MC; Smith L; Simon R; Sauter G; Oflazoglu E; Doronina SO; Meyer DL; Francisco JA; Carter P; Senter PD; Copland JA; Wood CG; Wahl AF
Cancer Res; 2006 Feb; 66(4):2328-37. PubMed ID: 16489038
[TBL] [Abstract][Full Text] [Related]
25. Cytotoxic Conjugates of Fibroblast Growth Factor 2 (FGF2) with Monomethyl Auristatin E for Effective Killing of Cells Expressing FGF Receptors.
Krzyscik MA; Zakrzewska M; Sørensen V; Sokolowska-Wedzina A; Lobocki M; Swiderska KW; Krowarsch D; Wiedlocha A; Otlewski J
ACS Omega; 2017 Jul; 2(7):3792-3805. PubMed ID: 30023704
[TBL] [Abstract][Full Text] [Related]
26. Halogenation at the Phenylalanine Residue of Monomethyl Auristatin F Leads to a Favorable
Sokka IK; Imlimthan S; Sarparanta M; Maaheimo H; Johansson MP; Ekholm FS
Mol Pharm; 2021 Aug; 18(8):3125-3131. PubMed ID: 34296616
[TBL] [Abstract][Full Text] [Related]
27. New insight on the structural features of the cytotoxic auristatins MMAE and MMAF revealed by combined NMR spectroscopy and quantum chemical modelling.
Johansson MP; Maaheimo H; Ekholm FS
Sci Rep; 2017 Nov; 7(1):15920. PubMed ID: 29162861
[TBL] [Abstract][Full Text] [Related]
28. Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models.
Li F; Emmerton KK; Jonas M; Zhang X; Miyamoto JB; Setter JR; Nicholas ND; Okeley NM; Lyon RP; Benjamin DR; Law CL
Cancer Res; 2016 May; 76(9):2710-9. PubMed ID: 26921341
[TBL] [Abstract][Full Text] [Related]
29. Novel Auristatins with High Bystander and Cytotoxic Activities in Drug Efflux-positive Tumor Models.
Moquist PN; Bovee TD; Waight AB; Mitchell JA; Miyamoto JB; Mason ML; Emmerton KK; Stevens N; Balasubramanian C; Simmons JK; Lyon RP; Senter PD; Doronina SO
Mol Cancer Ther; 2021 Feb; 20(2):320-328. PubMed ID: 33288628
[TBL] [Abstract][Full Text] [Related]
30. Minibody-Based and scFv-Based Antibody Fragment-Drug Conjugates Selectively Eliminate GD2-Positive Tumor Cells.
Kalinovsky DV; Kholodenko IV; Kibardin AV; Doronin II; Svirshchevskaya EV; Ryazantsev DY; Konovalova MV; Rozov FN; Larin SS; Deyev SM; Kholodenko RV
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674755
[TBL] [Abstract][Full Text] [Related]
31. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer.
Abdollahpour-Alitappeh M; Lotfinia M; Bagheri N; Sineh Sepehr K; Habibi-Anbouhi M; Kobarfard F; Balalaie S; Foroumadi A; Abbaszadeh-Goudarzi G; Abbaszadeh-Goudarzi K; Abolhassani M
J Cell Physiol; 2019 Mar; 234(3):2693-2704. PubMed ID: 30246298
[TBL] [Abstract][Full Text] [Related]
32. EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma.
Capone E; Lamolinara A; D'Agostino D; Rossi C; De Laurenzi V; Iezzi M; Iacobelli S; Sala G
J Control Release; 2018 May; 277():48-56. PubMed ID: 29550398
[TBL] [Abstract][Full Text] [Related]
33. Production of site-specific antibody-drug conjugates using optimized non-natural amino acids in a cell-free expression system.
Zimmerman ES; Heibeck TH; Gill A; Li X; Murray CJ; Madlansacay MR; Tran C; Uter NT; Yin G; Rivers PJ; Yam AY; Wang WD; Steiner AR; Bajad SU; Penta K; Yang W; Hallam TJ; Thanos CD; Sato AK
Bioconjug Chem; 2014 Feb; 25(2):351-61. PubMed ID: 24437342
[TBL] [Abstract][Full Text] [Related]
34. Lysosomal P-gp-MDR1 Confers Drug Resistance of Brentuximab Vedotin and Its Cytotoxic Payload Monomethyl Auristatin E in Tumor Cells.
Liu-Kreyche P; Shen H; Marino AM; Iyer RA; Humphreys WG; Lai Y
Front Pharmacol; 2019; 10():749. PubMed ID: 31379564
[TBL] [Abstract][Full Text] [Related]
35. Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker.
Oflazoglu E; Stone IJ; Gordon K; Wood CG; Repasky EA; Grewal IS; Law CL; Gerber HP
Clin Cancer Res; 2008 Oct; 14(19):6171-80. PubMed ID: 18809969
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic Efficacy of a Family of pHLIP-MMAF Conjugates in Cancer Cells and Mouse Models.
Burns KE; Hensley H; Robinson MK; Thévenin D
Mol Pharm; 2017 Feb; 14(2):415-422. PubMed ID: 28048942
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and Biological Evaluation of RGD and isoDGR-Monomethyl Auristatin Conjugates Targeting Integrin α
Raposo Moreira Dias A; Bodero L; Martins A; Arosio D; Gazzola S; Belvisi L; Pignataro L; Steinkühler C; Dal Corso A; Gennari C; Piarulli U
ChemMedChem; 2019 May; 14(9):938-942. PubMed ID: 30840356
[TBL] [Abstract][Full Text] [Related]
38. Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody-Drug Conjugate.
Anderson MG; Falls HD; Mitten MJ; Oleksijew A; Vaidya KS; Boghaert ER; Gao W; Palma JP; Cao D; Chia PL; John T; Gan HK; Scott AM; Reilly EB
Mol Cancer Ther; 2020 Oct; 19(10):2117-2125. PubMed ID: 32847977
[TBL] [Abstract][Full Text] [Related]
39. Antibody-Drug Conjugate Using Ionized Cys-Linker-MMAE as the Potent Payload Shows Optimal Therapeutic Safety.
Wang Y; Liu L; Fan S; Xiao D; Xie F; Li W; Zhong W; Zhou X
Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32245171
[TBL] [Abstract][Full Text] [Related]
40. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY
Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
